Monday, April 19, 2010 (Last Updated: 04/20/2010)
MONDAY, April 19 (HealthDay News) -- A novel application of the Prostate Health Index (PHI) and DNA content measures may effectively predict prostate cancer progression, though pro-prostate-specific antigen (PSA) levels alone may not, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 17 to 21 in Washington, D.C.
Sumit Isharwal, M.D., of the Johns Hopkins University School of Medicine in Baltimore, and colleagues evaluated 71 men enrolled in the Johns Hopkins Hospital active surveillance program using a new application of the PHI (which incorporates pro-PSA, free PSA and total PSA in the index) and DNA content measurements performed by image analysis.
The researchers found that the level of PHI was higher in men who were determined to have unfavorable biopsies, defined as an increase in grade or tumor volume. In addition, the DNA content in the biopsy tissue from the prostate gland adjacent to the cancer area and the area itself were effective predictors of a change to an unfavorable biopsy.
"Our findings were slightly surprising; serum pro-PSA level by itself was not able to predict unfavorable biopsy conversion in our Proactive Surveillance Program," study co-author, Robert W. Veltri, Ph.D., said in a statement. "However, PHI, which incorporates pro-PSA, free PSA and total PSA in the index, was significant for predicting unfavorable biopsy conversion."
The PHI was developed by Beckman-Coulter Inc.
Hematology & Oncology
OBGYN & Women's Health
Copyright © 2010 HealthDay. All rights reserved.